The battle for biotech drugs in India

The Indian biologic market is growing at an annual rate of around 30%. India is therefore seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

More features

Ozempic goes generic as Novo’s key patent expires

Sandoz strikes fresh biosimilar deal with South Korean biotech

US firm boosts patent bench with Desmarais hire

J&J unit targets former employee over alleged mass data theft

INTA: ‘New normal’ for in-house counsel as budgets fall

Emotional Perception: What next for patent holders?

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

The battle for biotech drugs in India

More on this story

Editor's picks

Editor's picks

More features